Academic Journal
Development of therapeutic PD-1 monoclonal antibodies for treatment of canine tumor.
| Τίτλος: | Development of therapeutic PD-1 monoclonal antibodies for treatment of canine tumor. |
|---|---|
| Συγγραφείς: | He J; Laboratory of Molecular Virology & Immunology, Haid Research Institute, Guangdong Haid Group Co., Ltd, Guangzhou 511434, China., Yin X; Laboratory of Molecular Virology & Immunology, Haid Research Institute, Guangdong Haid Group Co., Ltd, Guangzhou 511434, China., Xie A; Laboratory of Molecular Virology & Immunology, Haid Research Institute, Guangdong Haid Group Co., Ltd, Guangzhou 511434, China., Wang N; Laboratory of Molecular Virology & Immunology, Haid Research Institute, Guangdong Haid Group Co., Ltd, Guangzhou 511434, China., Guo Z; Laboratory of Molecular Virology & Immunology, Haid Research Institute, Guangdong Haid Group Co., Ltd, Guangzhou 511434, China., Chen Y; College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China., Cui W; Haid Pet Care Co., Ltd, Guangdong Haid Group Co., Ltd, Guangzhou 511434, China., Qian X; Haid Research Institute, Guangdong Haid Group Co., Ltd, Guangzhou 511434, China., Pan C; Laboratory of Molecular Virology & Immunology, Haid Research Institute, Guangdong Haid Group Co., Ltd, Guangzhou 511434, China. Electronic address: pancg01@Haid.com.cn. |
| Πηγή: | Veterinary immunology and immunopathology [Vet Immunol Immunopathol] 2026 Oct; Vol. 300, pp. 111189. Date of Electronic Publication: 2026 Aug 10. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Elsevier Scientific Country of Publication: Netherlands NLM ID: 8002006 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2534 (Electronic) Linking ISSN: 01652427 NLM ISO Abbreviation: Vet Immunol Immunopathol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [Amsterdam] Elsevier Scientific. |
| Ιατρικοί όροι (MeSH): | Antibodies, Monoclonal*/therapeutic use , Antibodies, Monoclonal*/immunology , Programmed Cell Death 1 Receptor*/immunology , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Neoplasms*/veterinary , Neoplasms*/drug therapy , Neoplasms*/immunology , Neoplasms*/therapy , Dog Diseases*/immunology , Dog Diseases*/drug therapy , Dog Diseases*/therapy, Immunotherapy/veterinary ; Enzyme-Linked Immunosorbent Assay/veterinary ; Animals ; Dogs ; Female |
| Περίληψη: | The use of monoclonal antibodies to block PD-1 binding to its ligand PD-L1 as a strategy for cancer treatment has already proven successful in the clinical management of human cancers. However, the clinical application of anti-PD-1 monoclonal antibodies in canine cancer immunotherapy still requires systematic and in-depth research. In this study, an anti-canine PD-1 monoclonal antibody (designated 2H4) was developed that can be used for therapeutic purposes. In an Indirect Enzyme-Linked Immunosorbent Assay (ELISA), the minimum binding concentration of 2H4 for PD-1E (a recombinant canine PD-1 extracellular domain protein) was 0.48 ng/mL. In the PD-1/PD-L1 blocking assay, the minimum concentration of 2H4 required to block PD-1/PD-L1 interaction was 3.9 ng/mL. Further studies identified the spatial region containing three PD-1 amino acid residues-Y68, K78, and E136-as the binding site for 2H4. In therapeutic trials using a Beagle tumor model, the 2H4 antibody demonstrated the ability to activate the Beagles' anti-tumor immune response without causing any side effects. However, due to the limitations of xenograft animal models and the potential impact of murine antibodies on therapeutic efficacy, there was no significant difference in the rate of tumor shrinkage between the 2H4 antibody treatment group and the control group. Nevertheless, following subsequent tumor implantation, tumor volume in the antibody treatment group decreased significantly. The results suggest that 2H4 has potential for the treatment of tumors. In future, this antibody will need to undergo canine-specific modification, and dogs with spontaneous cancer will need to be selected to further evaluate its clinical efficacy. (Copyright © 2026 The Authors. Published by Elsevier B.V. All rights reserved.) |
| Competing Interests: | Declaration of Competing Interest The antibody described in this article has been patented. |
| Contributed Indexing: | Keywords: Canine tumor; Monoclonal antibodies; PD-1; Therapy |
| Substance Nomenclature: | 0 (Antibodies, Monoclonal) 0 (Programmed Cell Death 1 Receptor) |
| Entry Date(s): | Date Created: 20260811 Date Completed: 20260929 Latest Revision: 20260929 |
| Update Code: | 20260930 |
| DOI: | 10.1016/j.vetimm.2026.111189 |
| PMID: | 42580049 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1873-2534 |
|---|---|
| DOI: | 10.1016/j.vetimm.2026.111189 |